



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appl. No.

10/822,639

Confirmation No.:1937

Applicant(s)

Pappin et al.

Filed

04/12/2004

TC/A.U.

1654

Examiner

Marcela M. Cordero Garcia

For

Mixtures of Isobarically Labeled Analytes and

Fragment Ions Derived

Therefrom

Customer No.

23544

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as life class mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on

atricia E. Tocci

INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Applicants submit herewith patents, publications or other information (listed on the attached Form PTO 1449) of which they are aware, which may be material to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 CFR §1.56.

This Information Disclosure Statement:

- (a) [] accompanies a new patent application submitted herewith.
- (b) [] is filed within three months after the filing date of the application or within three months after the date of entry of the national stage of a PCT application as set forth in 37 CFR §1.491.
- (c) [] as far as is known to the undersigned, is filed before the mailing date of a first Office action on the merits.
- (d) [] as far as is known to the undersigned, is filed before the mailing date of a first

- Office action after the filing of a request for continued examination under § 1.114.

 (e) [x] is filed after the first Office Action and more than three months after the application's filing date or PCT national stage date of entry filing but, as far as is known to the undersigned, prior to the mailing date of either a final action under §1.113, a notice of allowance under §1.311, whichever occurs first, and is accompanied by either the fee (\$180) set forth in 37 CFR §1.17(p) or a certification as specified in 37 CFR §1.97(e), as checked below. Should any fee be due, the U.S. Patent and Trademark Office is hereby authorized to charge Deposit Account No. 01-2213 in the amount of \$180.00 to cover the cost of this Information Disclosure Statement. Any deficiency or overpayment should be charged or credited to this deposit account. A duplicate of this sheet is enclosed.
- (f) [] is filed after the mailing date of either a final rejection or a notice of allowance, but on or before the payment of the issue fee, and is accompanied by the fee (\$180) set forth in 37 CFR §1.17(i)(1) and a certification as specified in 37 CFR §1.97(e), as checked below. This document is to be considered as a petition requesting consideration of the information disclosure statement. The U.S. Patent and Trademark Office is hereby authorized to charge Deposit Account No. 01-2213 in the amount of \$180.00 to cover the cost of this Information Disclosure Statement. Any deficiency or overpayment should be charged or credited to this deposit account. A duplicate of this sheet is enclosed.

[If either of boxes (e) or (f) is checked above, the following "certification" under 37 CFR §1.97(e) may need to be completed.] The undersigned certifies that:

[]	Each item of information contained in the information disclosure statement was first cited in a communication mailed from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this information disclosure statement.
[]	No item of information contained in this information disclosure statement was cited in a communication mailed from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this information disclosure statement
А сор	y of the items on PTO Form 1449 that are not United States Publications:
\boxtimes	are supplied herewith.

are not supplied because they were previously cited by or submitted to the Office

in prior application Serial No. _____, filed _____ and relied upon in this application for an

iM 108877 - 2 -

earlier filing date under 35 USC §120.

Appl. No. 10/822,639

While the information and references disclosed in this Information Disclosure Statement may be "material" pursuant to 37 CFR §1.56, it is not intended to constitute an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

In accordance with 37 CFR §1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR §1.56(a) exists. It is submitted that the Information Disclosure Statement is in compliance with 37 CFR §1.98 and MPEP §609 and the Examiner is respectfully requested to consider the listed references.

Respectfully submitted,

Date: JUNE 8, 2006

Brian D. Gildea

Attorney for Applicants

Reg. No. 39,995

Telephone: 508-383-7632

Customer No.: 23544
Applied Biosystems
500 Old Connecticut Path

Framingham, MA 01701 USA

Son Q. Gilde

iM 108877 - 3 -

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
to a collection of information unless to discontinuous collection.

phder the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of	2
------------	---

Complete if Known				
Application Number	10/822,639			
Filing Date	04/12/2004			
First Named Inventor	Pappin, Darryl			
Group Art Unit	1654			
Examiner Name	Marcela M Cordero Garcia			
Attorney Docket No.	BP0309US-CP1			

U.S. PATENT DOCUMENTS					
U.S. Patent D	ocument .		Date of Publication		
Number	Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	of Cited Document MM-DD-YYYY	Pages, Columns, Lines Where Relevant Passages of Relevant Figures Appear	
7,045,296	В2	Applera Corp and Institute for Systems Biology	05/16/2006		

	FOREIGN PATENT DOCUMENTS							
Cite	Foreign Patent Document			N	Date of Publication	Pages, Columns, Lines		
No.1	Office ³	Number ⁴	Kind Code ^s (if known)	Name of Patentee or Applicant of Cited Document	of Cited Document MM-DD-YYYY		T ⁶	
BS W003/056343 A		A	James, Peter	07/10/2003				
BT W004/086050 A		Proteome Sciences	10/07/2004					
BU EP 0990047 B1		Qiagen Genomics	05/14/2003					

	OTHER ART - NON PATENT LITERATURE DOCUMENTS						
Examiner Cit Initials* No		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.					
GF		Applied Biosystems Application Note iTRAQ Reagents: "Multiplex Protein Quantitation in Saccharomyces cerevisiae using iTRAQ Reagents with the QSTAR XL System and the 4700 Proteomics Discovery System" May 2004					
	GL	Bartlet-Jones, Michael et al, "Peptide Ladder Sequencing by Mass Spectrometry Using a Novel, Volatile Degradation Reagent", Rapid Communications in Mass Spectrometry, Vol. 8, 737-742 (1994)					
	GM	Gygi S P et al, "Quantitative Analysis of Complex Protein Mixtures Using Isotope-Coded Affinity Tags", Nature Biotechnology, vol. 17, no. 10, October 1999, pgs 994-999					
	GN	Huang, Yulin et al, "A Method for High Efficiency Peptide Sequencing Using Combined Enzymatic Digestion and Chemical Derivatization on MALDI MSMS", Applied Biosystems Poster Number 1159, 6 th International Symposium on Mass Spectrometry					
Examiner Signature		Date Considered					

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁸ Applicant is to place a check mark here if English language Translation is attached.

Complete if Known Substitute for form 1449A/PTO **Application Number** 10/822,639 Filing Date 04/12/2004 INFORMATION DISCLOSURE **First Named Inventor** Pappin, Darryl STATEMENT BY APPLICANT **Group Art Unit** 1654 Marcela M Cordero (Use as many sheets as necessary) **Examiner Name** Garcia Sheet 2 Attorney Docket No. BP0309US-CP1

	in the Health and Life Sciences, August 24-28, 2003, San Francisco.	
GO	Munchbach M et al: "Quantitation and Facilitated De Novo Sequencing of Proteins by Isotopic N-Terminal Labeling of Peptides with a Fragmentation-Directing Moeity", Analytical Chemistry, vol. 72, no. 17, 9/1/2000, pgs. 4047-4057	
 GP	Ross, Philip et al, "Investigation of Chemical Derivatization for Peptide CID Using LC-MALDI TOF MS/MS", Applied Biosystems Poster Number ThPF 250, ASMS Conference June 8 - June 12, 2003	
GQ	Ross, Philip et al, "Multiplexed protein quantitation in saccharomyces cerevisiae using amine-reactive isobaric tagging reagents", Molecular & Cellular Proteomics, December 2004, vol. 3, no. 12, pgs 1154-1169	
GR	Roth, K.D. et al, "Charge Derivatization of Peptides for Analysis by Mass Spectrometry", Mass Spectrometry Reviews, John Wiley and Sons, vol. 17, no. 4, 1998, pgs. 255-274	
GS	Sherman, Nicholas et al, "A Novel N-Terminal Derivative Designed to Simplify Peptide Fragmentation", 43 rd ASMS Conference on Mass Spectrometry and Allied Topics, 1995	
GT	Zieske, L.R. et al, "Protein and Biomarker Quantitation Using iTRAQ Reagents - A Novel Set of Multiplexed Amine-Specific Tagging Reagents", 6 th Sienna Meeting: From Genome to Proteome, September 2004.	

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ³ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.